# Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy

> **NCT06279754** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Xinxiang Medical College** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Recombinant Human Endostatin Injection

## Key facts

- **NCT ID:** NCT06279754
- **Lead sponsor:** The First Affiliated Hospital of Xinxiang Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-18
- **Primary completion:** 2024-06-18
- **Final completion:** 2025-12-18
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06279754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06279754, "Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06279754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*